MedTrace Logo

Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI

NCT00507338 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2009-01-09

No results posted yet for this study

Summary

ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their primary treatment for heart attack.

Conditions

  • Acute Myocardial Infarction

Interventions

PROCEDURE

PCI

early PCI for NSTEMI; primary PCI for STEMI

Sponsors & Collaborators

  • Archemix Corp.

    lead INDUSTRY

Principal Investigators

  • Michael Gibson, MD · Harvard Medical School, Beth Israel Deaconess Medical Center

  • Franz-Josef Neumann, MD · Herz-Zentrum Bad Krozingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00507338 on ClinicalTrials.gov